Eoflow (294090) Q3 2025 earnings summary

Executive summary

• Report covers the nine months ended September 30, 2025, for a medical device company specializing in wearable insulin pumps and related diabetes management solutions.

• The company is a key competitor in the global wearable insulin pump market, with proprietary technology and several product lines, including EOPatch and EOPatchX.

• Operations include domestic and international subsidiaries, with a focus on R&D and expansion into artificial pancreas systems.

Financial highlights

• Consolidated revenue for the nine months ended September 30, 2025, was ₩3.5 billion, down from ₩4.6 billion in the prior year period.

• Operating loss widened to ₩105.2 billion from ₩33.4 billion year-over-year.

• Net loss attributable to shareholders was ₩121.7 billion, compared to a net loss of ₩34.6 billion in the prior year.

• Gross margin improved to 3.7% from negative 14.8% year-over-year.

• Cash and cash equivalents at period end were ₩236 million, down from ₩2.6 billion at the previous year-end.

Outlook and guidance

• Management is implementing measures to improve liquidity and financial stability, including cost reductions, operational efficiency, and negotiations with creditors.

• The company is pursuing further R&D and regulatory approvals for next-generation products, including integrated artificial pancreas systems.